Hola,
Are you new here?

I have an account

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

PERSIST-SEQ

financed

Closed

Building a reproducible single cell experimental workflow to capture tumour cell...

Building a reproducible single cell experimental workflow to capture tumour cell persistence It is the ambition of PRESIST-SEQ to provide a new gold standard in single-cell experimental workflows the cancer research community by developing best practices, standard operating procedures (SOPs), and high-quality FAIR data, w... see more

30/06/2026

WECF INTERNATIONAL

15M€

Project Budget: 15M€

Project leader

STICHTING WOMEN ENGAGE FOR ACOMMON FUTURE - I... No se ha especificado una descripción o un objeto social para esta compañía.

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 16 Participantes

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2021-06-28

IMI2-2020-20-04: Tumour plasticity Specific Challenge:The last decade has seen tremendous advances in the development of effective targ...

I+D

Cerrada does 5 years

0% 46% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

16 Participantes

WECF INTERNATIONAL

2.16M€ | Leader

XENOPAT

375.00K€ | participant

BAYER AKTIENGESELLSCHAFT

995.00K€ | participant

FPO

7.83K€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 60 months Date Start: 2021-06-28
End date: 2026-06-30

Project leader

STICHTING WOMEN ENGAGE FOR ACOMMON FUTURE - I... No se ha especificado una descripción o un objeto social para esta compañía.

Project Budget 15M€

participation deadline Sin fecha límite de participación.

Project description It is the ambition of PRESIST-SEQ to provide a new gold standard in single-cell experimental workflows the cancer research community by developing best practices, standard operating procedures (SOPs), and high-quality FAIR data, with the ultimate aim to empower them to unravel therapeutic resistance. Such, that the community can identify urgently needed markers to predict, prevent, and target tumour resistance. Cancer takes 9.6 million lives each year, 90% of which result from untreatable metastatic relapse occurring after initially (seemingly) effective treatment. Therapeutic resistance is hence a primary cause of cancer death that clinically cannot be predicted, prevented, or treated. Addressing the urgent need for smarter therapeutic strategies is however held back by the lack of standardised experimental approaches that enable studying the biology of residual disease and drug tolerant persister cells in full detail. This need encompasses best practices for single-cell sequencing, advanced modelling techniques using patient-derived organoids and xenografts, and data FAIRification for integrated experiments. To address this need, PERSIST-SEQ brings together globally leading groups in single-cell sequencing technologies, cancer modelling and therapeutic resistance. Furthermore, the consortium has a broad range of clinical samples, cell lines, 3D models (PDX and PDOs) and mice models (GEMMs) at its disposal that can be leveraged to answer a broad range of emerging questions. This positions the consortium excellently to (1) design and standardise single-cell experimental approach to study the biology of therapeutic resistance and (2) initiate the largest single-cell profiling initiative on therapeutic resistance. Importantly, PERSIST-SEQ is organised such that it can quickly adapt to emerging insights and techniques during the project, and that ensures the capture of learnings in manners that stimulate replication of workflows elsewhere.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers